EGFR and neoplasm: The application of Sel-Cap liquid biopsy in a retrospective, longitudinal monitoring study suggests that highly sensitive platforms for EGFR resistance mutation T790M in plasma may allow for prediction of disease progression around 5 months in advance, unlike tumor re-biopsy or less sensitive liquid biopsy, where the T790M is often detected after disease progression.